Protocolens
FDA-approved

Semaglutide

Also known as: Ozempic, Wegovy, Rybelsus, GLP-1 receptor agonist

GLP-1 receptor agonist (incretin mimetic)

Overview

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a gut hormone the body releases after eating. It slows gastric emptying, increases satiety, and enhances glucose-dependent insulin secretion, which together tend to reduce appetite and food intake. It is one of the best-studied compounds in this dataset, with large Phase 3 RCTs supporting its FDA-approved indications. A documented consideration during GLP-1 therapy is loss of lean (muscle) mass alongside fat mass, which is why adequate protein intake and resistance training are commonly recommended alongside use. This is educational information, not a recommendation to use semaglutide; it is a prescription medication that must be prescribed and supervised by a licensed clinician.

Commonly Reported Uses

These are uses commonly discussed or marketed by users and vendors — not a list of proven or approved benefits, and not a recommendation.

  • Chronic weight management (FDA-approved as Wegovy)
  • Type 2 diabetes glycemic control (FDA-approved as Ozempic / Rybelsus)
  • Cardiovascular risk reduction in specific populations (FDA-approved indication)
  • Discussed off-label for general body-recomposition and 'cutting' goals — not an approved use

What to Track

Data points you and your clinician might monitor. For observation only — not a diagnostic protocol.

  • Body weight — daily smart-scale trend with a 7-day rolling average (expect gradual loss)
  • Body composition — InBody/DEXA skeletal muscle mass (SMM) and body-fat mass every 2–4 weeks; watch that SMM is preserved, not just total weight dropping
  • Nutrition — MyFitnessPal protein intake (commonly cited target ~1.6–2.2 g/kg body weight to support lean mass) and caloric adherence
  • Labs — HbA1c, fasting glucose, fasting insulin, lipid panel (triglycerides, LDL, HDL) at baseline and follow-up
  • Whoop — resting heart rate and recovery trend (under-fueling can degrade recovery)
  • Subjective — appetite, nausea/GI tolerance, energy

Sources & References

  1. [1]FDA — Wegovy (semaglutide) prescribing information and approvals
  2. [2]Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) — NEJM/PubMed
  3. [3]Semaglutide effects on body composition and biomarkers — PMC
  4. [4]GLP-1 and muscle loss: semaglutide, tirzepatide and lean mass — clinician overview

Quick Reference

Class
GLP-1 receptor agonist (incretin mimetic)
Evidence Level
FDA-approved
Reported Uses
4 listed
Tracking Metrics
6 suggested
Citations
4 sources

Safety & Legal Notes

FDA-approved, prescription-only. Common side effects are gastrointestinal (nausea, vomiting, diarrhea, constipation); boxed warning regarding thyroid C-cell tumors in rodent studies (relevance to humans unclear) and contraindications including personal/family history of medullary thyroid carcinoma or MEN 2. Loss of lean mass during treatment is documented. Not banned in sport as a standard therapeutic, but athletes should verify current rules with their governing body. Compounded semaglutide exists but carries additional quality/sourcing risk — the FDA has warned about compounded versions. Must be prescribed and monitored by a licensed clinician.

Track your protocol in Protocolens

Connect your InBody, Whoop, smart scale, and nutrition data. See your Overlay — all metrics, one clear read.

Get started free →
← All entries